FundedIQ
Biotechnology

BiomEdit: Funding, Investors & Team (Sep 2026)

BiomEdit is a company that uses innovative technology to develop new probiotics, bioactives, and microbial medicines for animal health. Their goal is to tackle important issues in animal agriculture and food security by harnessing the power of the microbiome. BiomEdit's unique platform uses high-throughput sequencing and data analytics to quickly identify and test new probiotic species and bioactive compounds. These can be modified to enhance production of beneficial substances or boost immune responses. These products are designed to improve animal health without relying on antibiotics.

www.biomedit.com LinkedIn Fishers, United States 11-50 employees
Total raised
$18.4M
Rounds
1
Latest
Series B
Jul 2025

BiomEdit has raised $18.4M across 1 funding round on record, the most recent a Series B of $18.4M announced in Jul 2025.

That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

BiomEdit Company Profile and Key Stats

Total funding raised
$18.4M
across 1 round on record
Funding rounds on record
1
Latest funding round
Series B
$18.4M in Jul 2025
Employees
11-50
reported band
Headquarters
Fishers, United States

Latest funding round on record: Jul 2025.

BiomEdit Funding Rounds

Date
Round
Amount
Series B
$18.4M

BiomEdit Founders and Leadership Team

Name
Role
Contact
Aaron Schacht
Founder
Locked

Contact details for the BiomEdit team: 1 of 1 has an email address on file.

Start 14-day free trial →

BiomEdit Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,182
$8.0M
29,795
$7.5M
4,307
$30M

BiomEdit's latest round of $18.4M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like BiomEdit in Biotechnology and Fishers

Companies Similar to BiomEdit

Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…

Series B $65.5M

Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…

Seed $7.0M

ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…

Series C $10.0M

EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…

Series A $35.0M

Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…

Convertible Note $3.5M

Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…

Convertible Note $6.8M

XiltriX North America is an information technology company that specializes in monitoring, predictive…

Undisclosed round $3.0M

Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…

Seed $3.1M

Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…

Series D $66.0M

Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…

Series B $92.7M

Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…

Series C $110M

InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…

Series B $77.0M

BiomEdit Funding FAQs

What does BiomEdit do?

BiomEdit is a company that uses innovative technology to develop new probiotics, bioactives, and microbial medicines for animal health. Their goal is to tackle important issues in animal agriculture and food security by harnessing the power of the microbiome. BiomEdit's unique platform uses high-throughput sequencing and data analytics to quickly identify and test new probiotic species and bioactive compounds. These can be modified to enhance production of beneficial substances or boost immune responses. These products are designed to improve animal health without relying on antibiotics.

How much funding has BiomEdit raised?

BiomEdit has raised $18.4M across 1 round on record. The most recent is a Series B of $18.4M announced in Jul 2025.

When did BiomEdit last raise funding?

BiomEdit's most recent funding round on record is a Series B of $18.4M, announced in Jul 2025.

Who founded BiomEdit?

FundedIQ lists Aaron Schacht (Founder) at BiomEdit.

Where is BiomEdit headquartered?

BiomEdit is based in Fishers, Indiana, United States.

How many employees does BiomEdit have?

BiomEdit is in the 11-50 employee band.

How does BiomEdit's funding compare to other Biotechnology startups?

BiomEdit's latest round of $18.4M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.

About FundedIQ's BiomEdit Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for BiomEdit is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.